Preview

Вестник дерматологии и венерологии

Расширенный поиск

Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management

https://doi.org/10.25208/0042-4609-2016-0-2-32-40

Полный текст:

Аннотация

The review summarizes and systemizes available international data on the pathogenesis, clinical manifestations and current recommendations for the management of rosacea patients.

Об авторе

JAMES Del Rosso
Del Rosso Dermatology Research Center
Россия


Список литературы

1. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013: 69: S27-S35.

2. Crawford G.H., Pelle M.T., James W.D. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341.

3. Spoendlin J., Voegel J.J., Jick S.S., Meier C.R. A study on the epidemiology of rosacea in the UK. Br J Dermatol 2012; 167.

4. Wilkin J., Dahl M., Detmar M. et al. Standardized classification system of rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587.

5. Del Rosso J.Q. Advances in understanding and managing rosacea: part 1 connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol 2012; 5 (3): 16-25.

6. Del Rosso J.Q., Gallo R.L., Tanghetti E. et al. An evaluation of potential correlation between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013; 91 (suppl 3): 1-8.

7. Plewig G., Kligman A.M. Rosacea. In: Plewig G., Kligman A.M., Eds, 3rd Edition, Acne and Rosacea, Springer-Verlag, Berlin, Germany, 1975: 438-445.

8. Guzman-Sanchez D.A., Ishiuji Y., Patel T. et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007; 57: 800-805.

9. Rosina P., Zamperetti M., Giovannini A. et al. Videocapillaroscopic alterations in erythemato-telangiectatic rosacea. J Am Acad Dermatol 2006; 54: 100-104.

10. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis 2013; 92: 234-240.

11. Dirschka T., Tronnier H., Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150: 1136-41.

12. Torok H.M. Rosacea skin care. Cutis 2000; 66 (suppl 4): 14-16.

13. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis 2014; 93: 134-38.

14. Bamford J.T. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001; 20: 199-206.

15. Schwab V.D., Sulk M., Seeliger S. et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 53-62.

16. Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.

17. Steinhoff M., Buddenkotte J., Aubert J. et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.

18. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: S15-S26.

19. Casas C., Paul C., Lahfa M. et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol 2012; 21: 906-10.

20. Forton F.M. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol 2012; 26: 19-28.

21. McAleer M.A., Lacey N., Powell F.C. The pathophysiology of rosacea. G Ital Dermatol Venereol 2009; 144:663-671.

22. Fleischer A.B. Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol 2011; 10: 614-620.

23. Yamasaki K., Kanada K., Macleod D.T. et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131: 688-697.

24. Meyer-Hoffert U., Schröder J.M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011; 15: 16-23.

25. Sulk M., Seeliger S., Aubert J. et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012; 132: 1253-62.

26. Del Rosso J.Q. Advances in understanding and managing rosacea: part 2. The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol 2012; 5: 26-36.

27. Yamasaki K., Di Nardo A., Bardan A. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13: 975-980.

28. Yamasaki K., Gallo R.L. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol 2011; 15: 53-62.

29. Layton A., Thiboutot D. Emerging therapies in rosacea. J AmAcad Dermatol 2013; 69: S57-65.

30. Korting H.C., Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287-94.

31. Kennedy Carney C., Cantrell W., Elewski B.E. Rosacea: a review of current topical, systemic and light based therapies. G Ital Dermatol Venereol 2009; 144: 673-88.

32. Odom R., Dahl M., Dover J. et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis 2009; 84: 97-104.

33. Del Rosso J.Q. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol 2013; 69: S44-56.

34. Two A., Del Rosso J.Q. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol 2014; 7: 20-25.

35. Tanghetti E., Del Rosso J.Q., Thiboutot D. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis 2014; 93: 71-6.

36. van Zuuren E.J., Kramer S.F., Carter B.R. et al. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 2011; 165: 760-81.

37. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013; 92: 277-84.

38. Lazaridou E., Giannopoulou C., Fotiadou C. et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011; 9: 21-25.

39. Pelle M.T., Crawford G.H., James W.D. Rosacea II: therapy. J Am Acad Dermatol 2004; 51: 499-512.

40. Schlesinger T., Rowland C. et al. J Drugs Dermatol 2013; 12 (6): 664-667.

41. Coda A.B., Hata T., Miller J. et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69: 570-77.

42. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis 2014; 93 (1): 18-28.

43. Bakar O., Demirgay Z., Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43: 151-54.

44. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol 2004; 140: 489-90.

45. Kanada K.N., Nakatsuji T., Gallo R.L. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol 2012; 132: 1435-42.

46. Sapadin A.N., Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.

47. Del Rosso J.Q. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006; 78: 97-100.

48. Del Rosso J.Q. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol 2009; 8: 664-68.

49. Bikowski J.B. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003; 2: 234-45.

50. Del Rosso J.Q., Webster G.W., Jackson M. et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802.

51. Preshaw P.M., Novak M.J., Mellonig J. et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008; 79: 440-52.

52. Skidmore R., Kovach R., Walker C. et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.

53. Park H., Del Rosso J.Q. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol 2011; 4: 54-61.

54. Hieble J.P. Subclassification and nomenclature of alpha- and beta-adrenoreceptors. Curr Top Med Chem 2007; 7: 129-34.

55. Johnson J.M., Kellogg D.L. Local thermal control of human cutaneous circulation. J Appl Physiol 2010; 109: 1229-38.

56. Kim J.H., Oh Y.S., Ji J.H. et al. Rosacea (erythema-totelangiectatic type) effectively improved by topical xylometazoline. J Dermatol 2011; 38: 510-13.

57. Fowler J., Jarratt M., Moore A. et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies. Br J Dermatol 2012 Mar; 166 (3): 633-41.

58. Shanler S.D., Ondo A.L. Successful treatment of erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor antagonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-71.

59. Benkali K., Leoni M., Rony F. et al. Br J Dermatol. 2014 Feb 7. doi: 10.1111/bjd.12881. [Epub ahead of print].

60. Fowler J. Jr, Jackson M., Moore A. et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650-56.

61. Moore A., Kempers S., Murakawa G. et al. Longterm safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014; 13: 56-61.

62. Ilkovitch D., Pomerantz R.G. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol 2014; 70 (5): e109-10. doi: 10.1016/j.jaad.2014.01.853.

63. Routt E.T., Levitt J.O. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol 2014; 70: 37-8.

64. Dourmishev A.L., Dourmishev L.A., Schwartz R.A. Ivermectin: pharmacology and application in dermatology. International Journal of Dermatology. 2005; 44: 981-88.

65. Forstinger C., Kittler H., Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41: 775-77.

66. Salem D.A., El-Shazly A., Nabih N. et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis 2013; 17: 343-47.

67. Stein Gold L., Kircik L., Fowler J. et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13 (3): 316-23.

68. Stein Gold L., Kircik L., Fowler J. et al. Longtern safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014; 13 (11): 1380-1388.

69. Taieb A., Ortonne J.P., Ruzicka T. et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015; 172 (4): 1103-1110.

70. Bhatia N.D., Del Rosso J.Q. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol 2012; 11: 838-844.


Для цитирования:


. . Вестник дерматологии и венерологии. 2016;(2):32-40. https://doi.org/10.25208/0042-4609-2016-0-2-32-40

For citation:


Del Rosso J.Q. Cutaneous rosacea: a thorough overview of pathogenesis, clinical presentations, and current recommendations on management. Vestnik dermatologii i venerologii. 2016;(2):32-40. (In Russ.) https://doi.org/10.25208/0042-4609-2016-0-2-32-40

Просмотров: 161


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0042-4609 (Print)
ISSN 2313-6294 (Online)